Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 21, 2025
Subject: Extension of employment term for a former Chief Medical Officer serving as a Strategic Advisor.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding executive compensation arrangements.
Material Changes
Executive Transition Update:
- Background: Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025.
- Prior Arrangement: Dr. Roberts entered an Amended and Restated Employment Agreement to serve as Strategic Advisor through December 31, 2025.
- New Action: On November 21, 2025, the Company amended the agreement to extend Dr. Roberts' term as Strategic Advisor for an additional 12 months.
- New Expiration: The extended term expires on December 31, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing provides no forward-looking guidance, outlook, or general management commentary regarding business operations or financial performance.
Risks and Contingencies: No specific risks or contingencies are disclosed in this report. The filing notes that the description of the amendment is brief and refers readers to the full text of the Amendment filed as Exhibit 10.1 for complete terms.
Investor Verification Checklist
- Review Exhibit 10.1 (Amendment to Amended and Restated Employment Agreement) for specific compensation details, severance terms, and non-compete clauses associated with the extension.
- Verify the total cost of the extension against the company's most recent quarterly or annual report to assess impact on operating expenses.
- Confirm the strategic role and deliverables expected from Dr. Roberts during the extended advisory period.